Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Scrip asks what 2022 holds for deal-making; Pfizer looks for transactions to add to its top line; Sanofi unworried about JAK threat to Dupixent; what information do healthcare professionals want from pharma; and Amgen looks to its established brands for growth.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 11 February 2022, including: Scrip asks what 2022 holds for deal-making; Pfizer Inc. looks for transactions to add to its top line; Sanofi unworried about JAK threat to Dupixent; what information do healthcare professionals want from pharma; and Amgen, Inc. looks to its established brands for growth.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Pfizer Shopping For Deals That Will Add $25bn To 2030 Revenues" - Scrip, 9 Feb, 2022.)
(Also see "Sanofi Unruffled By JAK Threat To Dupixent" - Scrip, 4 Feb, 2022.)
(Also see "What Physicians Want: Less of Promotional Content" - Scrip, 7 Feb, 2022.)
(Also see "Amgen’s Growth Story Relies Mainly On Continuing Plot Lines" - Scrip, 8 Feb, 2022.)